Skip to content
value.today

Nuron Biotech, Inc.

🇺🇸 Exton, Pennsylvania, USABiotechnologyFounded 2009

Formerly Nuron Biotech LLC

Total raised
$53 M
2 rounds on record
Latest round
$23 M
Jan 2014
First round on record
Dec 2012
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Nuron Biotech, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2014$23 MNo. 2$10 to $50 million

Nuron Biotech, Inc.: Raise no. 2, Jan 2014

Investors in this round

7 investors had bought by the notice of Feb 12, 2014: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $36 M offered; $13 M still to sell
Smallest investment taken
$10,000
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew L. Romberger, Esq. · Executive Officer
  • Warren D. Cooper · Executive Officer, Director
  • Wendy D. DiCocco, CPA · Executive Officer
  • David D. Zeng, Ph.D. · Director
  • Gregory D. Brown · Director
  • Matthew Q. Reber · Director
  • Mukeshbhai D. Patel · Director
  • Shankar Musunuri · Director
  • Todd D. Davis · Director
  • Vithalbhai D. Dhaduk · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Andrew Romberger, Vice President and General Counsel. Source: SEC Form D, newest notice filed Feb 12, 2014. Read the notice at the SEC.

equitySEC
Dec 2012$30 MNo. 1$10 to $50 million

Nuron Biotech, Inc.: Raise no. 1, Dec 2012

Investors in this round

1 investor had bought by the notice of Jan 3, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,650,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Romberger, Esq. · Executive Officer
  • David C. Zeng, Ph.D. · Executive Officer, Director
  • Mark C. Ambrose · Executive Officer
  • Richard Dinovitz · Executive Officer
  • Shankar Musunuri · Executive Officer, Director
  • Vijay Tammara, Ph.D. · Executive Officer
  • Wendy C. DiCicco, CPA · Executive Officer
  • Gregory B. Brown · Director
  • Matthew Q. Reber · Director
  • Mukeshbhai D. Patel · Director
  • Todd C. Davis · Director
  • Vithalbhai D. Dhaduk · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • JMP Securities LLC (CRD 22208) · San Francisco, CaliforniaSold in CT, PA

Remarks in the notice

  • On fees: “In addition, a retainer of $50,000 was paid to JMP Securities LLC.”

Signed by Andrew Romberger, Vice President and General Counsel. Source: SEC Form D, newest notice filed Jan 3, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Nuron Biotech, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2014).

    SEC Form D · Feb 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2014

That is all the official record says: Nuron Biotech, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Nuron Biotech, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Nuron Biotech, Inc.
NameRoleNamed in
Andrew L. Romberger, Esq.Executive officerFeb 2014
Warren D. CooperExecutive officerFeb 2014
Wendy D. DiCocco, CPAExecutive officerFeb 2014
Andrew Romberger, Esq.Executive officerJan 2013
David C. Zeng, Ph.D.Executive officerJan 2013
Mark C. AmbroseExecutive officerJan 2013
Richard DinovitzExecutive officerJan 2013
Shankar MusunuriExecutive officerJan 2013
Vijay Tammara, Ph.D.Executive officerJan 2013
Wendy C. DiCicco, CPAExecutive officerJan 2013
David D. Zeng, Ph.D.DirectorFeb 2014
Gregory D. BrownDirectorFeb 2014
Matthew Q. ReberDirectorFeb 2014
Mukeshbhai D. PatelDirectorFeb 2014
Shankar MusunuriDirectorFeb 2014
Todd D. DavisDirectorFeb 2014
Vithalbhai D. DhadukDirectorFeb 2014
Warren D. CooperDirectorFeb 2014
David C. Zeng, Ph.D.DirectorJan 2013
Gregory B. BrownDirectorJan 2013
Todd C. DavisDirectorJan 2013